ACON Aclarion, Inc.
Price Chart
Executive Summary
Aclarion announced that its Nociscan MRS technology was used in an award-winning research study exploring immune-associated biological signatures in chronic low back pain. The study is exploratory and does not represent a near-term commercial milestone or regulatory decision.
Actionable Insight
The press release is scientific and forward-looking with no immediate commercial catalyst. Traders should not expect a material stock move from this news alone. Monitor for future clinical adoption or partnership announcements.
Key Facts
- Nociscan's MRS technology measured intradiscal propionic acid to identify immune-linked patient subtypes in Modic type 1 changes.
- The study received the 2026 ISSLS Best Paper Award and was conducted by University of Zurich, UCSF, and the REACH Center.
- Aclarion states the findings may expand Nociscan's clinical applications beyond surgical decision support, but this is early-stage research.
- No financial data, revenue, earnings, or guidance were provided in the press release.
Financial Impact
No near-term financial impact; study results are preliminary and do not affect current revenue or earnings.
Risk Factors
- The research is exploratory; no guarantee of clinical adoption or revenue generation.
- Forward-looking statements subject to regulatory and commercial risks.
- Small market cap ($8M) amplifies volatility on any news.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304126 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
2d ago
|
Press Release
| $3.49 awaiting T+20 | awaiting T+20 | — | $3.47 (−0.57%) |
|
Jun 1, 2026
4d ago
|
Press Release
| — | awaiting T+20 | — | — |
|
May 6, 2026
4w ago
|
Insider Cluster
| $3.28 $3.49 | ▲ +6.40% | ▲ +3.62% | $3.47 (+5.79%) |
|
May 5, 2026
4w ago
|
Press Release
| $3.20 $3.50 | ▲ +9.38% | ▲ +4.42% | $3.47 (+8.44%) |
|
Apr 22, 2026
6w ago
|
Press Release
| $3.73 $3.20 | ▼ −14.21% | ▼ −17.37% | $3.47 (−6.97%) |
|
Mar 19, 2026
11w ago
|
Press Release
| $3.26 $3.39 | ▲ +3.99% | ▼ −3.63% | $3.47 (+6.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access